Skip to content

Cholecystectomy TIming for Mild Acute Biliary Pancreatitis [CTIMAP]: a Società Lombarda di Chirurgia Observational Study

Cholecystectomy TIming for Mild Acute Biliary Pancreatitis [CTIMAP]: a Società Lombarda di Chirurgia Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07234136
Acronym
CTIMAP
Enrollment
445
Registered
2025-11-18
Start date
2022-04-12
Completion date
2024-12-31
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Acute Biliary Pancreatitis

Brief summary

CTIMAP is a prospective multicenter observational study on patients with Mild Acute Biliary Pancreatitis (MABP) treated with Same Admission Cholecystectomy (SAC) and Interval Cholecystectomy (IC). The rationale of this study is to investigate the timing of cholecystectomy after MABP applied by Lombard surgeons and compare SAC and IC, with the hypothesis that SAC would reduce the risk of recurrent Gallstones Related Events (GRE) without increasing the difficulty of surgery and postoperative complications.

Interventions

None listed

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* to be admitted with a diagnosis of acute pancreatitis, as defined according to 2012 Atlanta Criteria * pancreatitis is mild as defined according to 2012 Atlanta Criteria * the etiology of pancreatitis is a gallstone related (finding of stones or sludge in the gallbladder on in the main biliary duct) * be greater than or equal to 18 years old * provide signed and dated informed consent form * willing to comply with all study procedures and be available during the study

Exclusion criteria

* pregnancy or lactation * pancreatitis not related to a gallstone etiology * chronic pancreatitis * moderately severe or severe pancreatitis * alcohol abuse * anything that would place the individual at increased risk or prevent the individual's full compliance with or completion of the study.

Design outcomes

Primary

MeasureTime frame
Rate of 6-month readmission due to GRE after hospitalization for MABP6 months

Secondary

MeasureTime frame
30-day postoperative biliary complications rate after SAC and after IC in patients with MABPDay 30
30-day postoperative mortality rate after SAC and after IC in patients with MABPDay 30
Intraoperative complication rate during SAC and ICDay of SAC or IC
Rate of bail out procedures during SAC and ICDay of SAC or IC
30-day postoperative complications rate after SAC and after IC in patients with MABPDay 30
Operative times (minutes) of SAC and of IC in patients with MABPDay of SAC or IC
Postoperative length of stay (PO-LOS) after SAC and after IC in patients with MABPAt discharge
Total length of stay (T-LOS) of patients with MABP treated with SAC and with ICAt discharge
Rate of patients who after six months after discharge did not receive cholecystectomy (no-cholecystectomy group)6 months after discharge
Conversion to open laparotomy rate during SAC and during IC in patients with MABPDay of SAC or IC

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026